Compare NVST & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVST | DNTH |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.5B |
| IPO Year | 2019 | 2018 |
| Metric | NVST | DNTH |
|---|---|---|
| Price | $28.30 | $107.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $26.46 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 3.0M | 874.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.31 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $2,566,500,000.00 | $2,036,000.00 |
| Revenue This Year | $6.67 | N/A |
| Revenue Next Year | $3.55 | $29.48 |
| P/E Ratio | $48.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.77 | $18.08 |
| 52 Week High | $30.42 | $114.55 |
| Indicator | NVST | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | 59.17 |
| Support Level | $25.49 | $100.00 |
| Resistance Level | $28.43 | N/A |
| Average True Range (ATR) | 0.83 | 5.74 |
| MACD | 0.05 | 0.23 |
| Stochastic Oscillator | 52.51 | 68.18 |
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.